Loading...
OTCM
ATRX
Market cap0kUSD
Dec 01, Last price  
0.00USD
Jan 2017
-99.99%
Name

Adhera Therapeutics Inc

Chart & Performance

D1W1MN
No data to show
P/E
0.00
P/S
—
EPS
0.33
Div Yield, %
—
Shrs. gr., 5y
36.23%
Rev. gr., 5y
76.78%
Revenues
0k
19,440,0001,847,0007,449,00028,490,00018,137,0002,609,00014,732,0002,460,0002,236,0004,217,0002,115,000500,000680,0000076,186252,000000
Net income
2m
P
-2,141,000-28,609,000-32,163,000-26,877,000-52,372,000-59,220,000-8,046,000-27,753,000-29,424,000-9,546,000-1,571,000-6,477,0003,337,000-837,143-6,219,348-16,754,957-12,640,000-5,540,000-7,784,0002,352,000
CFO
-1m
L+112.78%
-7,686,000-19,168,000-31,279,000-14,753,000-46,463,000-40,474,000-7,525,000-16,801,000-16,117,000-4,391,000285,000-4,779,000-2,165,000-522,314-1,260,685-9,611,433-8,738,000-588,000-665,000-1,415,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
URL
https://adherathera.com/
IPO date
Apr 15, 1994
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT